Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events: A Randomized Controlled Trial

Article Abstract:

The cholesterol-lowering drug gemfibrozil can lower the risk of heart attack in men with low blood levels of HDL cholesterol, according to a study of 2,531 men. HDL cholesterol is the 'good' cholesterol that can protect people against heart disease.

Author: Hershman, Jerome M., Robins, Sander J., Collins, Dorothea, Wittes, Janet T., Papademetriou, Vasilios, Deedwania, Prakash C., Schaefer, Ernst J., McNamara, Judith R., Kashyap, Moti L., Wexler, Laura F., Rubins, Hanna Bloomfield
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
Health aspects

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Clinical utility of different lipid measures for prediction of coronary heart disease in men and women

Article Abstract:

The effect of lipids on coronary heart disease on both sexes was studied and results documented.

Author: D'Agostino, Ralph B., Schaefer, Ernst J., McNamara, Judith R., Sullivan, Lisa, Wilson, Peter W.F., Vasan, Ramchandran S., Pencina, Michael J., Ingelsson, Erik, Keyes, Michelle J., Contois, John H., Schoonmaker, Christopher
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2007
Science & research, Research, Diagnosis, Risk factors, Coronary heart disease, Lipids, Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol

Article Abstract:

Gemfibrozil may lower the risk of heart attack, stroke, and death in men with low levels of high-density lipoprotein (HDL) cholesterol without high total cholesterol levels. Researchers administered the cholesterol-lowering drug or a placebo to 2,531 men. After about five years, 17% of the drug-treated men and 22% of the placebo-treated men suffered a heart attack or died -- a 24% reduction in risk due to the drug therapy. Gemfibrozil increased HDL levels and decreased blood triglyceride levels, but did not change low-density lipoprotein (LDL) cholesterol levels.

Author: Wilt, Timothy J., Elam, Marshall B., Robins, Sander J., Collins, Dorothea, Schaefer, Ernst J., Rubins, Hanna Bloomfield, Schectman, Gordon, Anderson, James W., Wittes, Janet, Fye, Carol L., Faas, Fred H., Linares, Esteban
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1999
United States, Statistical Data Included, Drug therapy, Cholesterol, LDL, VLDL cholesterol lipoproteins, Stroke (Disease), Stroke, Hypercholesterolemia, Antilipemic agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Prevention, Heart attack, Cholesterol, HDL, HDL cholesterol lipoproteins, Gemfibrozil
Similar abstracts:
  • Abstracts: Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes
  • Abstracts: A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women
  • Abstracts: Accidental fetal lacerations during cesarean delivery: Experience in an Italian level III university hospital
  • Abstracts: Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment
  • Abstracts: Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.